Purchase Order 75F40124P00209
Award Date 6/6/24
Potential Completion Date 6/6/29
Potential Value $142K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Laurel, MD, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic analysis technologies. The contract, with a ceiling value of $417,372.48, is for preventative maintenance services on Illumina's NextSeq 2000 and NextSeq 500 sequencing platforms. The award does not utilize a set-aside designation. Illumina is a leading provider of genetic sequencing instruments, reagents, and...
- This firm fixed-price purchase order contract was awarded by the Food and Drug Administration (FDA), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing technologies. The $576,928.00 contract is for the procurement of an Illumina NextSeq2000 Sequencing System, including associated reagents and maintenance services. The contract has a period of performance through July 20, 2026. Illumina is a key technology provider for federal scientific and diagnostic...
- This is a $77,592.11 firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing systems and reagents. The order is for the addition of items from Requisition #1168475, with no set-aside designation. Illumina has a history of providing sequencing instruments, reagents, and related services to support genomic research and diagnostics across various federal agencies, including the National Institutes of Health (NIH),...
- This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the service and maintenance of one Illumina MiSeq sequencing system, with a ceiling value of $34,972.40 and a performance period ending on September 24, 2024. Illumina, a for-profit organization and manufacturer of goods, has been awarded numerous prime federal contracts and...
- This is a federal contract award from the Food and Drug Administration (FDA) to Illumina, Inc., a for-profit manufacturer of genetic sequencing instruments and related products. The contract is for $58,464.00 to provide preventive maintenance services for two Illumina MiSeq instruments over a 5-year period from April 2022 to July 2027. The contract is a Firm Fixed Price Purchase Order and does not have a set-aside designation. Illumina holds two significant Indefinite Delivery Vehicles (IDVs)...
- This is a firm fixed-price delivery order contract awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing technologies. The contract is for $12,450.00 to provide preventative maintenance services for Illumina's MISEQ sequencing system. The contract has an ultimate completion date of June 30, 2018 and does not utilize any set-aside designations. Illumina, headquartered in San Diego, California, is a...
- This is a $127,989.57 firm fixed-price delivery order awarded by the National Human Genome Research Institute, a civilian agency within the National Institutes of Health, to Illumina, Inc., a biotechnology company specializing in genetic sequencing technologies. The contract has a period of performance ending on July 30, 2026. Illumina, a for-profit manufacturer, has been awarded multiple federal contracts and blanket purchase agreements to provide a range of genomic sequencing platforms,...
- This is a firm fixed price delivery order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The contract has a ceiling value of $237,188.40 and no set-aside designation. Illumina will provide a range of sequencing systems, including NextSeq, NovaSeq, MiSeq, and iSeq, along with associated reagents, consumables, sample prep kits, sequencing chips, support plans, maintenance services, and...
- This is a $19,812.90 firm fixed-price purchase order contract awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and related products. The contract has an ultimate completion date of August 3, 2026 and was awarded on August 4, 2025. No set-aside designation was used. Illumina, a leading provider of DNA and RNA sequencing technologies, will deliver a range...
- This is a firm fixed-price delivery order for $39,982.41 awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genetic sequencing and analysis technologies. The contract provides Illumina reagent chemistry kits to support the agency's scientific research and diagnostic applications. This award is part of a larger $45 million Indefinite Delivery Contract the company holds with the U.S. Department of Agriculture (USDA) as well...